GlassScriptPhysician profile
James J Kwak
NPI 1578552865
$7,825.32
in general payments reported to CMS, 2019-2025
39 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $1,480 · 2021: $1,808 · 2022: $1,511 · 2023: $939 · 2024: $754 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.57 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,105.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,104.11 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $740.51 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $668.53 | 2020-2024 | |
| Amgen INC. | $664.82 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $629.74 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $351.17 | 2019-2022 | |
| Amarin Pharma, INC. | $311.22 | 2019-2021 | |
| Pfizer INC. | $197.58 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.15 | 2019-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $172.34 | 2019-2024 | Nexletol, Onzetra Xsail, Contrave |
| Abbott Laboratories | $144.41 | 2019-2024 | Freestyle Libre 3 |
| Eisai INC. | $142.92 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $127.28 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $107.96 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kwak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.